The relationship between the efficacy of amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria and preexisting antibodies against merozoite surface protein (MSP)-1, a blood-stage P. falciparum antigen, was investigated. The immunoglobulin G antibody response to different MSP-1 recombinant proteins was evaluated in plasma samples from Gabonese children with uncomplicated malaria who were treated with amodiaquine. The prevalence of anti-MSP-1 antibodies was similar among patients with either parasitological and clinical cure after treatment ( ) or treatment failure ( ) by day 28 (83% in n p 102 n p 51 both groups). However, associations between antibody responses to K1 and MAD20 allelic families and therapeutic success were found ( and , respectively). A high proportion of plasma samples rec-P ! .001 P p .034 ognizing several antigens was found in the cured group. This association was significant even when data were stratified by age, particularly for the K1 family antigens ( ). These results suggest that humoral immune P p .029 responses play a supportive role in the efficacy of amodiaquine treatment.
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In vivo resistance of Plasmodium falciparum against antimalarial drugs, as determined by rapidly increasing, persistent, or recurrent parasitemia or by a lack of clinical response after treatment, depends on not only the ability of the parasite to escape antimalarial drugs via resistance mechanisms but also host factors such as the immune responses that affect P. falciparum survival [1] . Antimalarial drugs should be effective in patients from all age groups, but studies done in Gabon [2, 3] showed an association between the age of the patient and the degree of therapeutic success. These observations suggest that the immunological background of the subjects might contribute to the therapeutic response. To our knowledge, only 2 studies have investigated the relationship between antibody responses and therapeutic success in patients. In both studies, performed in Senegal [4] and Thailand [5] , antibody responses against asparagine-alanine-asparagine-proline repeats of the circumsporozoite protein and ring erythrocyte surface antigen, respectively, were elevated in patients who were treated successfully, compared with patients with treatment-resistant infections.
In areas of high and stable malaria transmission, it is generally accepted that immunity to malaria develops with age after exposure to different P. falciparum infections. On the basis of in vitro and in vivo studies, it has been shown that immune responses against merozoite surface protein (MSP)-1 are potential targets for protective immune responses [6] . Indeed, human antibody responses to different regions of MSP-1 have been associated with protection against malaria [7] .
In Lambaréné (Gabon), the efficacy of amodiaquine (aminoquinoline compounds) for the treatment of uncomplicated P. falciparum malaria has been evaluated in 2 randomized clinical trials. Amodiaquine was compared with artesunate-amodiaquine in one trial [8] and with atovaquone-proguanil in another trial (S.B., unpublished data). Treatment success with amodiaquine (monotherapy) was clearly associated with an increase of age among Gabonese children. Further details of these 2 trials are given in the Appendix.
In the cohort of children treated with amodiaquine (monotherapy), we investigated the influence of preexisting antibodies to P. falciparum MSP-1 (conserved and polymorphic regions) on treatment efficacy. Three parameters were considered in evaluating anti-MSP-1 antibodies in both groups of patients (cured and noncured): prevalence of detectable IgG antibodies, relative levels of the antibodies, and the number of different block 2 antigens recognized by antibodies of each individual in the groups.
PATIENTS, MATERIALS, AND METHODS
Study area and population. The study was done at Albert Schweitzer Hospital in Lambaréné (Gabon) from January 1999 to January 2001. One hundred fifty-three outpatients (0.5-10 years old) with uncomplicated P. falciparum malaria were selected (after obtaining the written informed consent of a parent or a guardian). Uncomplicated malaria was defined as the presence of P. falciparum on thick blood smears (1000-200,000 parasites/mL), a tympanic temperature of 138ЊC, or a history of fever in the preceding 24 h. Any sign of severe disease and/ or intake of antimalarial treatment in the preceding 72 h was a criterion for exclusion.
Patients were assigned to receive amodiaquine (10 mg/kg/ day for 3 days) as tablets (Camoquin; Parke Davis) [8] or suspension (Flavoquine; Hoechst Marion Roussel) (S.B., unpublished data). The primary efficacy end point was the cure rate by day 28, with follow-up visits on days 1, 2, 3, 7, and 28. Patients were classified as cured or noncured according to World Health Organization guidelines [9] and as described elsewhere [8] .
Blood samples. The day of admission before treatment initiation, blood samples for parasite DNA analysis were collected by finger prick on filter paper (Isocode filters; Schleicher & Schuell), and blood samples for immunological study were collected by venipuncture. Plasma samples from healthy Scottish adult donors with no history of exposure to malaria infection and a pool of plasma samples from semi-immune donors served as negative and positive controls, respectively, for the immunological assays.
ELISAs. Eleven MSP-1 recombinant proteins derived from C-terminal, N-terminal, and polymorphic block 2 regions were used, as described elsewhere [10] . Total IgG was assessed by indirect ELISAs from plasma samples diluted 1:500 [10] .
For each antigen, the mean (ϩ3 SD) of the corrected optical density values of samples from Scottish donors defined the cutoff value that separated responders (optical density values above this threshold) from nonresponders (optical density values less than or equal to this threshold). A comparison of antibody response level against each antigen between cured and noncured patients was performed using the optical density median calculation. Negative values were set to zero.
MSP-1 block 2 genotyping. Parasite DNA was extracted from filter papers according to the manufacturer's instructions. DNA amplification was performed by use of nested polymerase chain reaction targeting MSP-1 gene block 2 types-K1, RO33, and MAD20 [11] .
Statistical methods.
Nonparametric tests were used to compare data, and Pearson's x 2 test was used for comparisons of categorical data. A logistic regression model was developed to estimate the relative impact of different baseline variables on the outcome of treatment with amodiaquine. The criterion for inclusion of variables in the model was the demonstration of a significant effect ( ) in the preceding univariate anal-P ! .05 yses. We thus identified the following variables: parasite density on day 0 and age (continuous variables) and recognition of K1 and MAD20 block 2 antigens (categorical variables). Results of statistical tests were considered to be significant if . P ! .05
RESULTS
One hundred fifty-three children were included and grouped, according to their parasitological and clinical response to amodiaquine treatment, as either cured ( ) or noncured n p 102 ( ). Table 1 summarizes age, sex, body weight, and clinical n p 51 data recorded on the day of admission.
Antibodies to MSP-1. Anti-MSP-1 IgG was assessed in all patients' plasma samples ( ), and responders were den p 153 fined as donors of plasma samples with detectable reactivity to у1 recombinant MSP-1 antigen used. The antigen derived from the C-terminal part of the molecule (MSP-1 19 ) was recognized most frequently (79% of donors), whereas only 1% of the donors had antibodies against the conserved N-terminal block 1. Prevalence of antibodies against the polymorphic block 2 antigens was 7%-33%. Among the 3 main different types of block 2, plasma samples of 43%, 18%, and 14% of donors yielded positive reactions with у1 antigen from the K1, RO33, and MAD20 types, respectively. block 2 genotyping of P. falciparum isolates from the same patients showed the following distribution of the different allelic types of block 2: K1, 45%; MAD20, 29%; and RO33, 26%. Relationship between antibody prevalence, antibody levels, and number of recognized block 2 antigens and efficacy of amodiaquine treatment. The prevalence of responders to MSP-1 was similar in the cured and noncured patients (83% in both groups). Antibody response to allelic block 2 type antigens was assessed, but no significant difference in the prevalence of responders to the K1 type (43% of responders in both groups) and RO33 type (16% among cured vs. 23% among noncured patients) was found, whereas the proportion of responders to the MAD20 type was significantly higher in the group of noncured patients ( ; 10% among cured vs. P p .022 23% among noncured patients). Antibody levels were compared between cured and noncured patients for each MSP-1 antigen tested. The highest antibody levels were against the MSP-1 19 antigen, with a median OD value of 1.01 (range, OD of 0.02-2.69). However, such high antibody levels against MSP-1 19 antigen were not associated with therapeutic outcome. Very low median optical density values (р0.02) against each of the different block 2 antigens were detectable but were not associated with outcome after amodiaquine treatment.
To analyze the capacity of donors' antibodies to recognize different MSP1 block 2 antigens, plasma samples were divided into 3 groups, those reacting with 0, 1, or у2 antigens. Reactivity with у2 antigens of the K1 type ( ) or MAD20 P p .0035 type ( ) was associated with the efficacy of amodiaquine P p .006 treatment. Such associations were still observed when nonresponders were excluded from the analysis ( for K1 P p .0008 type and for MAD20 type; table 2). There was a higher P p .034 proportion of responders to multiple antigens of the K1 and the MAD20 block 2 types in the cured group, compared with the noncured group. However, such an association was not found for the monomorphic RO33 block 2 type.
Relationship between age, parasite density, and number of recognized block 2 antigens and amodiaquine treatment. The prevalence of antibodies and the number of recognized MSP-1 block 2 antigens increased significantly with age (P p ). Thus, to exclude the influence of age on the therapeutic .0002 outcome, different cutoff values were tested, and patients were divided into 2 age groups: !4 and у4 years old. The number of recognized antigens was assessed in the cured and noncured patients from the 2 different age groups separately (table 2). In both age groups, children whose antibodies recognized у2 variants of the K1 block 2 type were significantly predominant in the cured group ( for patients !4 years old, and P p .029 for patients у4 years old). P p .022
In addition, the relative impact of parasite density, age, and anti-MSP-1 antibodies (K1 and MAD20 block 2 types) on the outcome of the treatment was assessed. We found a cumulative effect of parasite density, age, and antibody response to MAD20 antigens on the outcome of treatment ( , logistic regression). P p .01
DISCUSSION
The present study was undertaken to evaluate the contribution of humoral immune responses in children who were treated successfully or unsuccessfully with amodiaquine during a malarial attack. Thus, plasma samples from cured and noncured patients collected before treatment were analyzed for prevalence and levels of IgG antibodies to different regions of MSP-1 and the number of different MSP-1 block 2 proteins recognized by the antibodies of each individual.
We found that a high proportion of children living in this area where malaria is hyperendemic have antibodies to MSP-1 molecules, as reported elsewhere by other groups [10, 12] . Specifically, MSP-1 19 C-terminal protein was the most frequently recognized protein (79%) in both groups of patients, which confirms the prevalence reported from another area of high endemicity in Papua New Guinea [13] .
The efficacy of amodiaquine to treat uncomplicated P. falciparum malaria was not associated with the prevalence of antibodies against any single MSP-1 protein tested here. Otherwise, similar prevalence of responders to K1 and RO33 types were found, whereas a higher prevalence of antibodies against the MAD20 type was found in the noncured group.
We next considered the number of different MSP-1 proteins recognized by antibodies of cured and noncured patients, although the protective role of antibodies to variable regions of MSP-1 is not yet resolved [7, 10, 12, 14] . Of interest, we found that, in patients !4 or у4 years old, recovery after treatment with amodiaquine was associated with the recognition of 11 K1 type antigens. This result could be explained by the predominant prevalence of K1 alleles in the parasite populations from the study area, as reported by Kun et al. [15] and as confirmed here. Similar to results found in Lambaréné, the protective effects of detectable anti-block 2 antibodies on the incidence of malaria were strongest against the more common allelic types of block 2 in a prospective study in The Gambia [7] . In another study in Gabon [14] that used different MSP-1 peptides of the polymorphic block 2, we showed that an increase in the number of different peptides recognized was compatible with acquisition of antiparasite immunity.
The data provided here, therefore, indicate that, regardless of age, children with antibodies against different MSP-1 block 2 variants are more likely to recover after treatment with amodiaquine. Levels of anti-MSP-1 antibodies, although estimated only very crudely at a single serum dilution (1:500), seemed not to influence the outcome of the treatment. MSP-1 block 2 antigens, in contrast to MSP-3 molecules [4] , could be considered as a good marker for investigation of the influence of antibody responses on the therapeutic outcome of drug treatment, as shown in the present study. Even though we did not exclude the influence of other factors on the therapeutic response, such as differences in individual pharmacokinetic profiles [16] or genetic background of the host, our data support the role of IgG antibodies against MSP-1 block 2 in the therapeutic efficacy of amodiaquine. The exact immunological mechanisms involved remain to be elucidated.
elsewhere [8] . In case of treatment failure, the patients received a single dose of sulfadoxine/pyrimethamine (25 mg/kg and 1.25 mg/kg, respectively). Only patients who received amodiaquine alone or with placebo and who had an evaluable efficacy outcome by day 28 were included in the analysis of the study reported here. Forty-four children were excluded on the basis of the exclusion criteria (i.e., signs of severe disease and/or intake of antimalarial treatment in the preceding 72 h). One hundred sixty-six children remained in the clinical trial, and 153 plasma samples were available from them for the immunological assays.
